Vivek Subbiah: Excited to join as a panelist in the upcoming STAT statnews event “Cancer’s Breakthrough Engine”
Vivek Subbiah shared a post on LinkedIn:
“Save the Date! Excited to join as a panelist in the upcoming STAT statnews
event “Cancer’s Breakthrough Engine” moderated by the amazing Adam Feuerstein
When: Tuesday, December 19, 2023, 12:00 p.m. – 1:00 p.m. CST
alongside, American Association for Cancer Research President elect Dr. Patricia Lorusso, & Cancer Journal Editor-in-chief Suresh S. Ramalingam, MD
Join us as we dive into the world of Precision Medicine discussing successes, challenges, and cutting-edge approaches in precision cancer medicines, from TKI’s, IO, ADC’s and beyond”
For the registration click here.
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023